American Heart Association

Powerful cholesterol drug awaits FDA’s decision

By AMERICAN HEART ASSOCIATION NEWS

A second in a new class of drugs that sharply lowers cholesterol is set for federal approval by Thursday – a “game-changer” for the hardest-to-treat patients who are in danger of heart attacks and strokes.

For people with familial hypercholesterolemia, or FH, a genetic condition that […]

August 26th, 2015|Categories: Health|Tags: , , , |Comments Off on Powerful cholesterol drug awaits FDA’s decision

FDA approves new cholesterol drug

By AMERICAN HEART ASSOCIATION NEWS

For the first time in decades, the U.S. Food and Drug Administration on Friday approved a major new class of medicines to lower cholesterol, and thereby protect against heart attacks.

Praluent (alirocumab) from Sanofi and Regeneron Pharmaceuticals received approval and a second drug, Repatha (evolocumab) from […]

July 24th, 2015|Categories: Health|Tags: , , |4 Comments

After one year, patients on new drug fare better than standard therapy

Patients taking evolocumab—an investigational therapy previously shown to dramatically lower “bad” cholesterol—were half as likely to die, suffer a heart attack or stroke, be hospitalized or need a procedure to open blocked arteries compared with those who received standard care, according to research presented at the American College of […]